GlassScriptPhysician profile
Manjula Raguthu
NPI 1932162617
$1,089.64
in general payments reported to CMS, 2019-2025
11 companies · $36.38 in 2025
The $36.38 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $135 · 2021: $141 · 2022: $91.40 · 2023: $173 · 2024: $98.88 · 2025: $36.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $266.78 | 2019-2022 | |
| Galderma Laboratories, L.P. | $234.35 | 2020-2023 | |
| Lilly USA, LLC | $205.40 | 2022-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $124.99 | 2019 | |
| Boston Scientific Corporation | $123.23 | 2020 | |
| Medtronic USA, INC. | $46.83 | 2019 | |
| Abbott Laboratories | $23.67 | 2024 | Freestyle Libre 3 |
| Radius Health, INC. | $17.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.38 | 2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $15.91 | 2022 | |
| Si-Bone, INC. | $13.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjula Raguthu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.